Eight conventional and 14 biological drugs were prescribed: methotrexate was the preferred conventional drug overall (n=126, 57.0%) and for 9 of 11 uveitides, and adalimumab was the preferred ...

with adalimumab becoming the most commonly used b/tsDMARD. Researchers performed a serial cross-sectional study using ...

Treatment with CZP vs ADA may offer more consistent efficacy when used among patients with RA who have elevated RF levels.

A recent post hoc analysis of the EXXELERATE study revealed that certolizumab pegol (CZP) sustained drug concentration and ...

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

Comorbidities do not significantly impact treatment retention rates among patients with inflammatory RMDs who switch from originator to biosimilar adalimumab.

Cyltezo is a prescription drug used to treat certain inflammatory conditions. Learn about the side effects it can cause and how to manage them.

Whereas 89.5% of new prescriptions for disease-modifying anti-rheumatic drugs (DMARDs) in 2000 were for old-line agents, by ...

The daughter of a woman known as the "matriarch of the family" has paid tribute to her after she died from tuberculosis ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...